ESR1 and breast cancer: Several reports showed that higher levels of APOBEC3B expression was associated with decreased survival rates among estrogen receptor-positive (ER+) breast cancer patients [32] and a higher expression of APOBEC3B was independently associated with lower survival rates of ovarian cancer patients [12].